Aug 29,2022

Theranica Secures $45 Million Series C Funding Round

Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other idiopathic pain conditions, today announced the closing of its Series C funding round, with a first closing of $45 million.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Nov 11,2022

Luminopia, Inc. Announces Oversubscribed Seed Extension Financing Round

Luminopia, Inc., a prescription digital therapeutics company pioneering a new class of treatments for neuro-visual disorders, today announced an oversubscribed $5.7M seed extension financing round. ShangBay Capital led the round, with participation from Sony Innovation Fund, The Vertical Group, and SSI Strategy, as well as support from existing investors. With the closing of the round, William Dai, Founding Managing Partner of ShangBay Capital, will be joining Luminopia’s Board of Directors.

FUNDING SEED
View Analyst & Ambassador Comments
Go to original news
Jul 15,2021

Germany's Dopavision closes €12M Series A round for digital childhood myopia treatment

Berlin-based digital therapeutics company, Dopavision has announced the closing of a €12 million Series A financing round to develop its lead product for childhood myopia. Seventure Partners led the round and was joined by Novartis Pharmaceuticals and the company's existing shareholders, Boehringer Ingelheim Venture Fund and Ababax Health.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Jul 19,2021

Digital addiction treatment company Quit Genius scores $64M

Quit Genius, a digital treatment platform for addiction, closed a $64 million Series B funding round. The round was co-led by Kinnevik and Atomico, with additional participation from Octopus Ventures, Triple Point Ventures and Startup Health. This, in addition to the company's Series A round from last year, brings its total amount raised to $77.5 million.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Jul 19,2021

Chronic condition management startup Sweetch scores $20M

Sweetch, a startup that uses artificial intelligence to help patients manage chronic conditions, today landed $20 million in Series A funding. Entrée Capital led the funding, with participation from Tal Capital, Noaber, Kortex Ventures, Insurtech VC FinTLV Ventures, Philips, OurCrowd and Qure Ventures.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Jul 21,2021

Woebot Health Closes $90 Million Series B Funding Round Co-Led by JAZZ Venture Partners and Temasek

Woebot Health today announced it has closed a $90 million Series B funding round, bringing total investment in the company to $114 million. The round was co-led by existing investor JAZZ Venture Partners and Temasek with participation from funds and accounts managed by BlackRock Private Equity Partners and Owl Ventures. Additional participants include Mirae Asset Capital, Kicker Ventures, Alumni Ventures and Gaingels as well as existing investors NEA and AI Fund. Woebot Health will use the proceeds to accelerate further development of its relational platform and technologies, advance its lead digital therapeutic candidates, and expand its team and go-to-market activities to meet surging global demand for mental health care.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Jul 28,2021

Axenya raises a US$ 3 million Seed round and brings chronic disease management solutions to Brazil

Axenya, an Uruguayan digital therapy startup, has just announced a Seed funding round of around $3 million from Brazilian venture capital Igah, Ventures, big_bets and Alexia Ventures. With the round, the health tech startup begins its expansion beyond its home country through Brazil. The company plans to debut next in Mexico, Argentina, and Chile and to be operating in all of Latin America by the end of 2023.

FUNDING SEED
View Analyst & Ambassador Comments
Go to original news
Jul 28,2021

MedRhythms Closes $25M Series B Funding Led by Morningside Ventures and Advantage Capital to Advance Digital Therapeutics Platform

MedRhythms, a leader in developing prescription digital therapeutics that use sensors, software, and music to measure and improve walking for patients with a neurologic injury or disease, announced today the closing of a $25 million Series B financing round co-led by Morningside Ventures and Advantage Capital, with participation from existing investor Werth Family Investment Associates. The Company has raised a total of $34 million in gross proceeds from private financings since inception.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Aug 09,2021

S-Alpha Therapeutics, Inc., Digital Therapeutics Start-up Raises $8.7 Million in Series A Funding

S-Alpha Therapeutics, Inc., (“S-Alpha” CEO: Seung-Eun Choi), a startup dedicated in R&D for digital therapeutics, announced the completion of its Series A financing. S-Alpha Therapeutics raised a total of $8.7M USD (10 Billion KRW) in Series A financing round with the participation by existing investors and new Venture Capitalist (VC) funding. In 2020, S-Alpha Therapeutics raised $2.7M USD (3 Billion KRW) in seed round of funding from Hana Ventures, STIC Ventures, AJU IB Investment, SJ Investment Partners, and TONY Investment. In Series A funding, all existing investors participated in this investment, and Korea Investment Partners, Stonebridge Ventures, Devsisters Ventures/KDB Capital, and Timewise Investment participated as new investors.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Aug 11,2021

Mahana Therapeutics Secures $61 Million Series B Financing to Support Commercialization and Further Development of Digital Therapeutics

Mahana Therapeutics, a leading developer of prescription digital therapeutics designed to empower patients with chronic health conditions, has completed a $61 million Series B financing. The company will use the funds to launch the FDA-cleared prescription digital therapeutic Mahana™ IBS and accelerate development of several digital therapeutics for chronic health conditions.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Subscribe to FUNDING